Atea Pharmaceuticals, Inc.

For the period ended Sep 30, 2026. Filed Nov 9, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 9, 2026

AVIR$4.41+2.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

	September 30,2026	December 31,2025
Assets
Current assets
Cash and cash equivalents	$97,922	$95,713
Marketable securities	93,277	206,117
Prepaid expenses and other current assets	9,069	9,161
Total current assets	200,268	310,991
Property and equipment, net	145	457
Other assets	132	3,136
Operating lease right-of-use assets, net	161	634
Total assets	$200,706	$315,218
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable	$4,843	$12,945
Accrued expenses and other current liabilities	19,969	25,996
Current portion of operating lease liabilities	213	843
Total current liabilities	25,025	39,784
Commitments and contingencies (see Note 11)
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized; no shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively	—	—
Common stock, $0.001 par value; 300,000,000 shares authorized; 80,295,084 and 78,126,796 shares issued and outstandingas of September 30, 2026 and December 31, 2025, respectively	80	78
Additional paid-in capital	808,778	797,751
Accumulated other comprehensive (loss) gain	(73)	174
Accumulated deficit	(633,104)	(522,569)
Total stockholders’ equity	175,681	275,434
Total liabilities and stockholders’ equity	$200,706	$315,218

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.